24-month event-free survival (EFS24) is a reliable indicator of disease-related outcomes in patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL) treated with anthracycline-based immunochemotherapy (R-CHOP or similar regimens). Approximately 70% of patients achieve 24-month event-free survival after completing immunochemotherapy, and those who achieve EFS24 have overall survival comparable to the general population matched for age and gender.

In an international cohort study of 1,348 patients with diffuse large B-cell lymphoma treated with immunochemotherapy, we developed the IPI24 risk prediction model using the EFS24 clinical endpoint and validated it in an independent cohort of 1,177 patients.

IPI24 predicts the probability (0-100%) of achieving EFS24 for each patient and can be used for prognosis, treatment stratification, and risk assessment.